Literature DB >> 24019035

SEOM guide to antiemetic prophylaxis in cancer patients treated with chemotherapy 2013.

J García Gómez1, M E Pérez López, M Alonso Bermejo, Y Escobar Álvarez, J García Mata.   

Abstract

Chemotherapy-induced emesis (CIE) both in the form of nausea and vomiting is one of the adverse effects most feared by patients who receive treatment, and one of the factors that most affect their quality of life and limit their functional capacity for everyday activities. Chemotherapy-induced emesis can result from many factors, depending on the treatment and the patients themselves. The best treatment for CIE is prevention, based on the use of drugs aimed at inhibiting the signal of certain neurotransmitters involved in the process. Antiemetic prophylaxis for chemotherapy of high-emetogenous potential lasting 1 day includes a combination of anti-5-HT3, neurokinin-1 inhibitors and dexamethasone. Antiemetic prophylaxis for chemotherapy of moderate-emetogenous potential lasting 1 day includes a combination of palonosetron and dexamethasone. Prophylaxis is not recommended for chemotherapy with minimal emetogenous potential. In the case of unforeseen or refractory emesis the use of olanzapine, metoclopramide or phenothiazine should be considered.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24019035     DOI: 10.1007/s12094-013-1093-2

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  39 in total

Review 1.  Comparative review of 5-HT3 receptor antagonists in the treatment of acute chemotherapy-induced nausea and vomiting.

Authors:  P J Hesketh
Journal:  Cancer Invest       Date:  2000       Impact factor: 2.176

2.  A phase III open-label study to assess safety and efficacy of palonosetron for preventing chemotherapy-induced nausea and vomiting (CINV) in repeated cycles of emetogenic chemotherapy.

Authors:  Kenjiro Aogi; Hiroshi Sakai; Hirohisa Yoshizawa; Norikazu Masuda; Nobuyuki Katakami; Yasuhiro Yanagita; Kenichi Inoue; Masaru Kuranami; Mitsuhiro Mizutani; Noriyuki Masuda
Journal:  Support Care Cancer       Date:  2011-08-02       Impact factor: 3.603

Review 3.  Potential role of the NK1 receptor antagonists in chemotherapy-induced nausea and vomiting.

Authors:  P J Hesketh
Journal:  Support Care Cancer       Date:  2001-07       Impact factor: 3.603

Review 4.  Antiemetic activity of corticosteroids in patients receiving cancer chemotherapy: dosing, efficacy, and tolerability analysis.

Authors:  S M Grunberg
Journal:  Ann Oncol       Date:  2006-11-15       Impact factor: 32.976

5.  Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference.

Authors:  F Roila; P J Hesketh; J Herrstedt
Journal:  Ann Oncol       Date:  2005-11-28       Impact factor: 32.976

Review 6.  Efficacy of palonosetron (PAL) compared to other serotonin inhibitors (5-HT3R) in preventing chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately or highly emetogenic (MoHE) treatment: systematic review and meta-analysis.

Authors:  Tobias Engel Ayer Botrel; Otávio Augusto C Clark; Luciana Clark; Luciano Paladini; Enéas Faleiros; Bruna Pegoretti
Journal:  Support Care Cancer       Date:  2010-05-22       Impact factor: 3.603

7.  Contribution of dexamethasone to control of chemotherapy-induced nausea and vomiting: a meta-analysis of randomized evidence.

Authors:  J P Ioannidis; P J Hesketh; J Lau
Journal:  J Clin Oncol       Date:  2000-10-01       Impact factor: 44.544

8.  The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy.

Authors:  Rudolph M Navari; Cindy K Nagy; Sarah E Gray
Journal:  Support Care Cancer       Date:  2013-01-12       Impact factor: 3.603

9.  Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron.

Authors:  R Gralla; M Lichinitser; S Van Der Vegt; H Sleeboom; J Mezger; C Peschel; G Tonini; R Labianca; A Macciocchi; M Aapro
Journal:  Ann Oncol       Date:  2003-10       Impact factor: 32.976

10.  Efficacy and tolerability of transdermal granisetron for the control of chemotherapy-induced nausea and vomiting associated with moderately and highly emetogenic multi-day chemotherapy: a randomized, double-blind, phase III study.

Authors:  Ralph V Boccia; Lucio N Gordan; Gemma Clark; Julian D Howell; Steven M Grunberg
Journal:  Support Care Cancer       Date:  2010-09-12       Impact factor: 3.603

View more
  1 in total

1.  SEOM guidelines 2013: a response to the needs of Spanish oncologists.

Authors:  J J Cruz-Hernández; C A Rodríguez
Journal:  Clin Transl Oncol       Date:  2013-08-08       Impact factor: 3.405

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.